Testing for Inhibitors with Hemophilia

Overview

Hemophilia is an inherited bleeding disorder characterized by a lack of or low levels of certain proteins called clotting factors. These clotting factors are responsible for helping the blood to clot properly. There are several types of hemophilia, but they all involve low levels of either clotting factor VIII or factor IX.

Inhibitor testing is an important process for people with hemophilia to assess their risk of developing inhibitors. Inhibitors are antibodies that can interfere with the effectiveness of treatment for hemophilia. Testing for inhibitors helps doctors determine the best course of treatment and management for individuals with hemophilia.

Here's how inhibitor testing is done and when it should be performed:

• Screening Prior to Surgery or Invasive Procedures: It is recommended to perform inhibitor screening before any surgery or invasive procedure. This helps identify individuals who may be at risk of developing inhibitors during these procedures.
• Switching Treatment Products: Inhibitor screening is also recommended before and a few weeks after switching to a different treatment product. Although the risk of inhibitor development from product switching is generally low, it's still important to monitor for any potential issues.
• Proactive Screening for Non-Severe Hemophilia A: For individuals with non-severe hemophilia A, it is recommended to proactively screen for inhibitors approximately 6 weeks after surgery or treatment for a major bleed. This helps identify any potential development of inhibitors in these individuals.
• Genotype Analysis for Hemophilia B: In the case of hemophilia B, it is recommended to perform DNA analysis to identify the underlying genotype. This analysis can help identify individuals who may be at higher risk for inhibitor development.
• Regular Monitoring for Previously Untreated Patients (PUPs): All previously untreated patients (PUPs) should be closely monitored and regularly screened for inhibitors. The first 50 exposure days (ED) represent a high-risk period, so screening should be performed more frequently during this time.
• Ongoing Routine Follow-Up Screening: After the initial high-risk period, periodic screening should continue as part of the routine follow-up process. For severe hemophilia A patients, screening should be performed every three exposure days until 20 EDs, then every 10 EDs until 50 EDs, and later on at least two times a year until 150 EDs. After reaching 150 EDs, the risk of inhibitor development becomes very low.

It's important to note that inhibitor testing involves specialized blood tests that measure how long it takes for blood to clot. These tests include routine coagulation tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT). Additionally, a Bethesda assay with the Nijmegen modification can be used to detect inhibitors.

Remember, if you or someone you know has hemophilia and needs inhibitor testing, it's always best to consult with a healthcare professional who can provide personalized advice and guidance based on individual circumstances and medical history.